The following article appeared in the Financial Times on February 20th, 2015:
Overall about £84m was raised on equity crowdfunding platforms in 2014, triple the previous year’s amount, according to Nesta, an innovation charity.
Oval Medical Technologies, a device manufacturer, raised £1.1m last year on SyndicateRoom to begin producing a self-injecting device for people who are frightened of needles, for example.
Under SyndicateRoom’s lead investor structure, the investment was headed by Jonathan Milner, founder and former chief executive of the AIM-listed biotechnology company Abcam.
“People who were either in medical technology or were engineers were asking really informed questions,” says Barbara Lead, Oval’s chief executive. “I would certainly advise early stage companies to think about crowdfunding, but make sure you go for a platform that does its due diligence properly.”
Investors are entering largely uncharted territory.
Equity crowdfunding promises a financial return but very few funders have achieved a successful exit from their investments — the companies are mostly unlisted and the industry has only existed for four years.
You can link to the full article on FT.com here.